Literature DB >> 23430808

Cardiac Ultrasound Findings in Infants with Severe (Hurler Phenotype) Untreated Mucopolysaccharidosis (MPS) Type I.

L Schroeder1, P Orchard, C B Whitley, J M Berry, J Tolar, W Miller, E A Braunlin.   

Abstract

BACKGROUND: Serious cardiac valve disease and left ventricular hypertrophy occur in most untreated older children with severe mucopolysaccharidosis type I. Although it is assumed that early intervention prevents these processes, evaluation of cardiac findings in these infants has not yet been reported.
METHODS: We reviewed echocardiograms of 13 untreated infants < 1 year of age with severe mucopolysaccharidosis type I who had undergone evaluation for hematopoietic cell transplantation. We recorded left ventricular chamber dimensions, septal and posterior wall thicknesses, ventricular function, and aortic sinus diameters. We evaluated mitral and aortic valves for increased thickness, regurgitation, and stenosis.
RESULTS: Average age (7M, 6F) was 221 (range 25-347) days. Left ventricular chamber dimension was ≥2 SD of normal in 3/13; wall thicknesses were ≥2 SD of normal in 2/13 infants. Systolic function was normal. Mitral valves were thickened in all infants; mitral regurgitation was present in 9/13, but significant in only three infants. Aortic valves were thickened in 10/13, but no infant had significant aortic regurgitation. Neither mitral nor aortic stenosis occurred. Aortic roots were dilated to ≥2 SD of normal in 5/13.
CONCLUSIONS: Characteristic cardiac features of severe mucopolysaccharidosis type I can be seen in infancy. Mitral and aortic valve thickening are nearly universally present, even in the youngest infants. In 20-30 % of infants, other abnormalities such as left ventricular dilation, increased wall thickness, and mild mitral/aortic regurgitation may occur. Aortic root dilation is a frequent finding. Early intervention with enzyme replacement therapy may minimize the incidence and severity of cardiac findings in these infants.
SUMMARY: Serious cardiac valve disease and left ventricular hypertrophy occur in most untreated older children with severe mucopolysaccharidosis type I. Although it is assumed that early intervention prevents these processes, evaluation of cardiac findings in these infants has not yet been reported. In our study of 13 infants with severe untreated MPS I < 1 year of age, mitral and aortic valve thickening was nearly universally present and aortic root dilation was frequent. Despite this, we found a lower incidence of left ventricular hypertrophy and both a lower incidence and milder expression of mitral and aortic valve dysfunction than previously reported in older children. These findings suggest that earlier intervention, including neonatal screening, may be of benefit to children with severe MPS I.

Entities:  

Year:  2013        PMID: 23430808      PMCID: PMC3755584          DOI: 10.1007/8904_2012_208

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  21 in total

1.  Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up.

Authors:  A Tylki-Szymanska; A Jurecka; Z Zuber; A Rozdzynska; J Marucha; B Czartoryska
Journal:  Acta Paediatr       Date:  2011-06-29       Impact factor: 2.299

2.  Clear cells in the atrioventricular valves of infants with severe human mucopolysaccharidosis (Hurler syndrome) are activated valvular interstitial cells.

Authors:  Elizabeth Braunlin; Jakub Tolar; Shannon Mackey-Bojack; Tiwanda Masinde; William Krivit; Frederick J Schoen
Journal:  Cardiovasc Pathol       Date:  2010-07-09       Impact factor: 2.185

3.  Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up.

Authors:  Orazio Gabrielli; Lorne A Clarke; Stefano Bruni; Giovanni V Coppa
Journal:  Pediatrics       Date:  2009-12-21       Impact factor: 7.124

4.  Fatal coronary artery disease in an infant with severe mucopolysaccharidosis type I.

Authors:  Leonie van den Broek; Ad P C M Backx; Hans Coolen; Frits A Wijburg; Ron Wevers; Eva Morava; Chris Neeleman
Journal:  Pediatrics       Date:  2011-04-04       Impact factor: 7.124

5.  Echocardiographic study of paediatric patients with mucopolysaccharidosis.

Authors:  Gabriela N Leal; Ana C de Paula; Cláudio Leone; Chong A Kim
Journal:  Cardiol Young       Date:  2010-04-26       Impact factor: 1.093

6.  Ocular abnormalities in the mucopolysaccharidoses after bone marrow transplantation. Longer follow-up.

Authors:  E O Gullingsrud; W Krivit; C G Summers
Journal:  Ophthalmology       Date:  1998-06       Impact factor: 12.079

7.  Cardiovascular changes in children with mucopolysaccharide disorders.

Authors:  U R Mohan; A A Hay; M A Cleary; J E Wraith; R G Patel
Journal:  Acta Paediatr       Date:  2002       Impact factor: 2.299

8.  Cardiac manifestations of the mucopolysaccharidoses.

Authors:  R M Schieken; R E Kerber; V V Ionasescu; H Zellweger
Journal:  Circulation       Date:  1975-10       Impact factor: 29.690

9.  Cardiovascular changes in children with mucopolysaccharide storage diseases and related disorders--clinical and echocardiographic findings in 64 patients.

Authors:  J H Dangel
Journal:  Eur J Pediatr       Date:  1998-07       Impact factor: 3.183

10.  The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses.

Authors:  Vlasta Fesslová; Paola Corti; Giovanna Sersale; Attilio Rovelli; Pierluigi Russo; Savina Mannarino; Gianfranco Butera; Rossella Parini
Journal:  Cardiol Young       Date:  2009-02-06       Impact factor: 1.093

View more
  7 in total

1.  Aortic root dilatation in patients with mucopolysaccharidoses and the impact of enzyme replacement therapy.

Authors:  Fabiano de Oliveira Poswar; Carolina Fischinger Moura de Souza; Roberto Giugliani; Guilherme Baldo
Journal:  Heart Vessels       Date:  2018-08-22       Impact factor: 2.037

Review 2.  Skeletal dysplasias: A radiographic approach and review of common non-lethal skeletal dysplasias.

Authors:  Ananya Panda; Shivanand Gamanagatti; Manisha Jana; Arun Kumar Gupta
Journal:  World J Radiol       Date:  2014-10-28

3.  The effect of neonatal gene therapy with a gamma retroviral vector on cardiac valve disease in mucopolysaccharidosis VII dogs after a decade.

Authors:  Paul W Bigg; Meg M Sleeper; Patricia A O'Donnell; Yuli Liu; Susan Wu; Margret L Casal; Mark E Haskins; Katherine P Ponder
Journal:  Mol Genet Metab       Date:  2013-06-25       Impact factor: 4.797

Review 4.  Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation.

Authors:  Seth J Rotz; Thomas D Ryan; Salim S Hayek
Journal:  J Thromb Thrombolysis       Date:  2020-11-24       Impact factor: 2.300

5.  Elevated cerebral spinal fluid biomarkers in children with mucopolysaccharidosis I-H.

Authors:  Gerald V Raymond; Marzia Pasquali; Lynda E Polgreen; Patricia I Dickson; Weston P Miller; Paul J Orchard; Troy C Lund
Journal:  Sci Rep       Date:  2016-12-02       Impact factor: 4.379

6.  Aortic Root Dilatation in Mucopolysaccharidosis I-VII.

Authors:  Meena Bolourchi; Pierangelo Renella; Raymond Y Wang
Journal:  Int J Mol Sci       Date:  2016-11-29       Impact factor: 5.923

Review 7.  Mucopolysaccharidosis Type I: A Review of the Natural History and Molecular Pathology.

Authors:  Christiane S Hampe; Julie B Eisengart; Troy C Lund; Paul J Orchard; Monika Swietlicka; Jacob Wesley; R Scott McIvor
Journal:  Cells       Date:  2020-08-05       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.